|
Cannabis Campaigners' Guide News Database result:
|
|
UK: GW Expands Trials On Cannabis Drugs
Financial Times
Thursday 11 Apr 2002 Shares in GW Pharmaceuticals rose more than 3 per cent on Thursday after the UK group announced it was expanding late-stage clinical trials of its cannabis-based medicines. The new trials, which will involve about 600 patients, supplement the phase three trials already in progress, including the use of cannabis medicines for multiple sclerosis, cancer and nerve damage pain. "The start of four new phase three clinical trials heralds the achievement of another key milestone in our progress towards first regulatory submission for our products," said Geoffrey Guy, executive chairman. The company is aiming to make its first submission for approval of the medicine, which is administered by means of an under-the-tongue spray, next year. Although the UK government has recently softened its stance on personal use of the drug in some parts of London, possession of the drug remains illegal in the UK. GW, which has been given a special licence to grow cannabis, said the government had indicated that it would amend the Misuse of Drugs Act to allow the prescribing of cannabis-based medicines, once the product had been licenced. The group's shares rose 4p, or 3.2 per cent, to reach 130p shortly after the announcement before falling back to 126.5p by midday in London.
After you have finished reading this article you can click here to go back.
|
This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!